Adapt Pharma Teams with Smith Medical Partners to Support Distribution of Free NARCAN® (Naloxone HCl) Nasal Spray Offer to All U.S. High Schools

DUBLIN, April 28, 2016 /PRNewswire/ -- Adapt Pharma, Limited (www.adaptpharma.com), today announced Smith Medical Partners, LLC (www.smpspecialty.com), as their distribution partner for their previously announced program to offer a free carton of NARCAN® (Naloxone HCl) Nasal Spray to every high school in the United States. This announcement follows the Adapt Pharma grant awarded to the National Association of School Nurses (NASN) to fund their educational efforts to increase awareness of opioid-related risks among students, educators, families and communities.  

NARCAN® Nasal Spray is the first and only FDA-approved naloxone nasal spray for the emergency treatment of opioid-, fentanyl- and heroin-related overdose. It is now available as a ready-to-use, needle-free, 4 mg concentrated dose of naloxone in a single spray. As the first and only FDA-approved naloxone nasal spray, NARCAN® Nasal Spray provides a ready-to-use alternative to currently available opioid overdose emergency treatments. NARCAN® Nasal Spray is not a substitute for emergency medical care.  Please see Indications and Important Safety Information below.

To find out more information about how your state and local school district can participate in the NARCAN® Nasal Spray High School Program and to obtain a free carton for your local school, please visit: http://www.narcannasalspray.com/how-to-get-nns/partnerships/ or call 1-844-4NARCAN® (462-7226).

"The team at Smith Medical Partners is excited to partner with Adapt Pharma as its distribution partner to support its offer of a free carton of NARCAN® Nasal Spray for each high school. We strive to provide the highest quality support to our customers to help them care for their communities," said Robert Rash, Vice President, Smith Medical Partners. "For years, we have made available some of the most important and impactful emergency response tools, such as the EpiPen® by Mylan. For schools especially, providing access to these medications can have an impact on the entire community and potentially prevent harmful or fatal situations."

Opioid abuse and overdose is a national epidemic. A 2013 national survey on drug use and health showed that there were 2.2 million adolescents aged 12 to 17 who were current illicit drug users.¹

"Our distribution partnership with Smith Medical Partners is a key milestone in implementing high school access to a medication that can make an impact when seconds may count," said Mike Kelly, President, U.S. Operations, Adapt Pharma. "This device will equip those in our communities– families, friends, caregivers and school nurses – with a tool they can rely on without need for medical training or expertise."

For questions regarding NARCAN® distribution, please call 1-844-4NARCAN® (462-7226).

To read the terms and conditions and participate in the NARCAN® Nasal Spray High School Program, fill out the certification form available online.

ABOUT NARCAN® (naloxone HCl) NASAL SPRAY
NARCAN® Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.

NARCAN® Nasal Spray is not a substitute for emergency medical care. Always seek emergency medical assistance in the event of a suspected, potentially life-threatening opioid emergency after administration of the first dose of NARCAN® nasal spray.

If the desired response is not obtained after 2 or 3 minutes, administer an additional dose of NARCAN® Nasal Spray using a new NARCAN® Nasal Spray. If the patient responds to NARCAN® Nasal Spray and relapses back into respiratory depression before emergency assistance arrives, administer an additional dose and continue surveillance of the patient. If there is still no response and additional doses are available, administer additional doses of NARCAN® Nasal Spray every 2 to 3 minutes using a new NARCAN® Nasal Spray with each dose until emergency medical assistance arrives. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.

Please see Indications and Important Safety Information below. 

Please see full prescribing information for NARCAN® Nasal Spray, available at http://www.NARCANnasalspray.com/pdf/NARCAN-Prescribing-Information.pdf

AVAILABILITY OF NARCAN® NASAL SPRAY

NARCAN® Nasal Spray was made available in February of 2016.

Qualifying group purchasers may source NARCAN® Nasal Spray directly from wholesalers and distributors. To place a pre-order immediately or for assistance in sourcing NARCAN® Nasal Spray please contact Adapt Pharma's dedicated Customer Service Team at 844-4-NARCAN® (844-462-7226) or email [email protected].

NARCAN® NASAL SPRAY INDICATIONS AND IMPORTANT SAFETY INFORMATION

Indications

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.

NARCAN® Nasal Spray is not a substitute for emergency medical care. 

Important Safety Information

NARCAN^® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, increased heart rate (tachycardia), fever, runny nose, sneezing, goose bumps (piloerection), sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may be characterized by convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product, available here: http://www.narcannasalspray.com/pdf/NARCAN-Prescribing-Information.pdf. 

Additional information, including full prescribing information for NARCAN® Nasal Spray, and important safety information and instructions for use, is also available at www.NARCAN®NasalSpray.com.

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN® (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  

ABOUT ADAPT PHARMA
Adapt Pharma is a privately-held pharmaceutical company committed to positively impacting the lives of patients. Adapt Pharma's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development, and FDA approved, pharmaceutical products. Adapt Pharma's company headquarters is in Dublin, Ireland and its U.S. headquarters is in Radnor, Pennsylvania. For more information, please visit www.adaptpharma.com.

For Media Inquiries

Thom Duddy, Adapt Pharma
Executive Director, Communications
Mobile: 484-532-5470
Email: [email protected]

¹ King, R., Embrey, ML. Adopted June 2015. National Association of School Nurses, Naloxone Use in the School Setting: The Role of the School Nurse. Accessed March 16, 2016. https://www.nasn.org/PolicyAdvocacy/PositionPapersandReports/NASNPositionStatementsFullView/tabid/462/ArticleId/854/Naloxone-Use-in-the-School-Setting-The-Role-of-the-School-Nurse-Adopted-June-2015.

Logo - http://photos.prnewswire.com/prnh/20160410/353440LOGO 
Logo - http://photos.prnewswire.com/prnh/20160410/353441LOGO

SOURCE Adapt Pharma

Related Links

http://adaptpharma.com